Global Duchenne Muscular Dystrophy Drugs Market Insights, Forecast to 2025

1 Study Coverage

• 1.1 Duchenne Muscular Dystrophy Drugs Product Introduction
• 1.2 Market Segments
• 1.3 Key Duchenne Muscular Dystrophy Drugs Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type
  • 1.4.2 Development & Drug Target
  • 1.4.3 Mechanism of Action (MoA)
  • 1.4.4 Route of Administration (RoA)
  • 1.4.5 Molecule Type
• 1.5 Market by Application
  • 1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application
  • 1.5.2 Hospitals and Clinics
  • 1.5.3 Medical Laboratories
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Duchenne Muscular Dystrophy Drugs Market Size, Estimates and Forecasts
  • 2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2015-2026
  • 2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026
• 2.2 Global Duchenne Muscular Dystrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Duchenne Muscular Dystrophy Drugs Competitor Landscape by Players

• 3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
  • 3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020)
  • 3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers (2015-2020)
• 3.2 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers
  • 3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020)
  • 3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2019
  • 3.2.5 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
• 3.4 Duchenne Muscular Dystrophy Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2015-2020)
  • 4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020)
  • 4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020)
  • 4.1.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Type (2021-2026)
  • 4.2.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Duchenne Muscular Dystrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2015-2020)
  • 5.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020)
  • 5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Application (2015-2020)
  • 5.1.3 Duchenne Muscular Dystrophy Drugs Price by Application (2015-2020)
• 5.2 Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Duchenne Muscular Dystrophy Drugs Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Duchenne Muscular Dystrophy Drugs by Country
  • 6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
  • 6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
• 6.3 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

7 Europe

• 7.1 Europe Duchenne Muscular Dystrophy Drugs by Country
  • 7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
  • 7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
• 7.3 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Duchenne Muscular Dystrophy Drugs by Region
  • 8.1.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
  • 8.1.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
• 8.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Duchenne Muscular Dystrophy Drugs by Country
  • 9.1.1 Latin America Duchenne Muscular Dystrophy Drugs Sales by Country
  • 9.1.2 Latin America Duchenne Muscular Dystrophy Drugs Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
• 9.3 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Country
  • 10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country
  • 10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
• 10.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

11 Company Profiles

• 11.1 Akashi Therapeutics Inc
  • 11.1.1 Akashi Therapeutics Inc Corporation Information
  • 11.1.2 Akashi Therapeutics Inc Description and Business Overview
  • 11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.1.5 Akashi Therapeutics Inc Related Developments
• 11.2 Antisense Therapeutics Ltd
  • 11.2.1 Antisense Therapeutics Ltd Corporation Information
  • 11.2.2 Antisense Therapeutics Ltd Description and Business Overview
  • 11.2.3 Antisense Therapeutics Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.2.5 Antisense Therapeutics Ltd Related Developments
• 11.3 Beech Tree Labs Inc
  • 11.3.1 Beech Tree Labs Inc Corporation Information
  • 11.3.2 Beech Tree Labs Inc Description and Business Overview
  • 11.3.3 Beech Tree Labs Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.3.5 Beech Tree Labs Inc Related Developments
• 11.4 Biogen Inc
  • 11.4.1 Biogen Inc Corporation Information
  • 11.4.2 Biogen Inc Description and Business Overview
  • 11.4.3 Biogen Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.4.5 Biogen Inc Related Developments
• 11.5 Bioleaders Corp
  • 11.5.1 Bioleaders Corp Corporation Information
  • 11.5.2 Bioleaders Corp Description and Business Overview
  • 11.5.3 Bioleaders Corp Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.5.5 Bioleaders Corp Related Developments
• 11.6 BioMarin Pharmaceutical Inc
  • 11.6.1 BioMarin Pharmaceutical Inc Corporation Information
  • 11.6.2 BioMarin Pharmaceutical Inc Description and Business Overview
  • 11.6.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.6.5 BioMarin Pharmaceutical Inc Related Developments
• 11.7 Biophytis SAS
  • 11.7.1 Biophytis SAS Corporation Information
  • 11.7.2 Biophytis SAS Description and Business Overview
  • 11.7.3 Biophytis SAS Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.7.5 Biophytis SAS Related Developments
• 11.8 Capricor Therapeutics Inc
  • 11.8.1 Capricor Therapeutics Inc Corporation Information
  • 11.8.2 Capricor Therapeutics Inc Description and Business Overview
  • 11.8.3 Capricor Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.8.5 Capricor Therapeutics Inc Related Developments
• 11.9 Catabasis Pharmaceuticals Inc
  • 11.9.1 Catabasis Pharmaceuticals Inc Corporation Information
  • 11.9.2 Catabasis Pharmaceuticals Inc Description and Business Overview
  • 11.9.3 Catabasis Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.9.5 Catabasis Pharmaceuticals Inc Related Developments
• 11.10 CRISPR Therapeutics
  • 11.10.1 CRISPR Therapeutics Corporation Information
  • 11.10.2 CRISPR Therapeutics Description and Business Overview
  • 11.10.3 CRISPR Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.10.5 CRISPR Therapeutics Related Developments
• 11.1 Akashi Therapeutics Inc
  • 11.1.1 Akashi Therapeutics Inc Corporation Information
  • 11.1.2 Akashi Therapeutics Inc Description and Business Overview
  • 11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
  • 11.1.5 Akashi Therapeutics Inc Related Developments
• 11.12 Daiichi Sankyo Co Ltd
  • 11.12.1 Daiichi Sankyo Co Ltd Corporation Information
  • 11.12.2 Daiichi Sankyo Co Ltd Description and Business Overview
  • 11.12.3 Daiichi Sankyo Co Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Daiichi Sankyo Co Ltd Products Offered
  • 11.12.5 Daiichi Sankyo Co Ltd Related Developments
• 11.13 Debiopharm International SA
  • 11.13.1 Debiopharm International SA Corporation Information
  • 11.13.2 Debiopharm International SA Description and Business Overview
  • 11.13.3 Debiopharm International SA Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Debiopharm International SA Products Offered
  • 11.13.5 Debiopharm International SA Related Developments
• 11.14 Editas Medicine Inc
  • 11.14.1 Editas Medicine Inc Corporation Information
  • 11.14.2 Editas Medicine Inc Description and Business Overview
  • 11.14.3 Editas Medicine Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Editas Medicine Inc Products Offered
  • 11.14.5 Editas Medicine Inc Related Developments
• 11.15 Eloxx Pharmaceuticals Inc
  • 11.15.1 Eloxx Pharmaceuticals Inc Corporation Information
  • 11.15.2 Eloxx Pharmaceuticals Inc Description and Business Overview
  • 11.15.3 Eloxx Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Eloxx Pharmaceuticals Inc Products Offered
  • 11.15.5 Eloxx Pharmaceuticals Inc Related Developments
• 11.16 F. Hoffmann-La Roche Ltd
  • 11.16.1 F. Hoffmann-La Roche Ltd Corporation Information
  • 11.16.2 F. Hoffmann-La Roche Ltd Description and Business Overview
  • 11.16.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 F. Hoffmann-La Roche Ltd Products Offered
  • 11.16.5 F. Hoffmann-La Roche Ltd Related Developments
• 11.17 FibroGen Inc
  • 11.17.1 FibroGen Inc Corporation Information
  • 11.17.2 FibroGen Inc Description and Business Overview
  • 11.17.3 FibroGen Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 FibroGen Inc Products Offered
  • 11.17.5 FibroGen Inc Related Developments
• 11.18 Fulcrum Therapeutics Inc
  • 11.18.1 Fulcrum Therapeutics Inc Corporation Information
  • 11.18.2 Fulcrum Therapeutics Inc Description and Business Overview
  • 11.18.3 Fulcrum Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Fulcrum Therapeutics Inc Products Offered
  • 11.18.5 Fulcrum Therapeutics Inc Related Developments
• 11.19 Galapagos NV
  • 11.19.1 Galapagos NV Corporation Information
  • 11.19.2 Galapagos NV Description and Business Overview
  • 11.19.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 Galapagos NV Products Offered
  • 11.19.5 Galapagos NV Related Developments
• 11.20 Genethon SA
  • 11.20.1 Genethon SA Corporation Information
  • 11.20.2 Genethon SA Description and Business Overview
  • 11.20.3 Genethon SA Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 Genethon SA Products Offered
  • 11.20.5 Genethon SA Related Developments
• 11.21 GTx Inc
  • 11.21.1 GTx Inc Corporation Information
  • 11.21.2 GTx Inc Description and Business Overview
  • 11.21.3 GTx Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.21.4 GTx Inc Products Offered
  • 11.21.5 GTx Inc Related Developments
• 11.22 Santhera Pharmaceuticals Holding AG
  • 11.22.1 Santhera Pharmaceuticals Holding AG Corporation Information
  • 11.22.2 Santhera Pharmaceuticals Holding AG Description and Business Overview
  • 11.22.3 Santhera Pharmaceuticals Holding AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.22.4 Santhera Pharmaceuticals Holding AG Products Offered
  • 11.22.5 Santhera Pharmaceuticals Holding AG Related Developments
• 11.23 Sarepta Therapeutics Inc
  • 11.23.1 Sarepta Therapeutics Inc Corporation Information
  • 11.23.2 Sarepta Therapeutics Inc Description and Business Overview
  • 11.23.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.23.4 Sarepta Therapeutics Inc Products Offered
  • 11.23.5 Sarepta Therapeutics Inc Related Developments
• 11.24 SOM Biotech SL
  • 11.24.1 SOM Biotech SL Corporation Information
  • 11.24.2 SOM Biotech SL Description and Business Overview
  • 11.24.3 SOM Biotech SL Sales, Revenue and Gross Margin (2015-2020)
  • 11.24.4 SOM Biotech SL Products Offered
  • 11.24.5 SOM Biotech SL Related Developments
• 11.25 Strykagen Corp
  • 11.25.1 Strykagen Corp Corporation Information
  • 11.25.2 Strykagen Corp Description and Business Overview
  • 11.25.3 Strykagen Corp Sales, Revenue and Gross Margin (2015-2020)
  • 11.25.4 Strykagen Corp Products Offered
  • 11.25.5 Strykagen Corp Related Developments
• 11.26 Summit Therapeutics Plc
  • 11.26.1 Summit Therapeutics Plc Corporation Information
  • 11.26.2 Summit Therapeutics Plc Description and Business Overview
  • 11.26.3 Summit Therapeutics Plc Sales, Revenue and Gross Margin (2015-2020)
  • 11.26.4 Summit Therapeutics Plc Products Offered
  • 11.26.5 Summit Therapeutics Plc Related Developments
• 11.27 Taiho Pharmaceutical Co Ltd
  • 11.27.1 Taiho Pharmaceutical Co Ltd Corporation Information
  • 11.27.2 Taiho Pharmaceutical Co Ltd Description and Business Overview
  • 11.27.3 Taiho Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.27.4 Taiho Pharmaceutical Co Ltd Products Offered
  • 11.27.5 Taiho Pharmaceutical Co Ltd Related Developments
• 11.28 Teijin Pharma Ltd
  • 11.28.1 Teijin Pharma Ltd Corporation Information
  • 11.28.2 Teijin Pharma Ltd Description and Business Overview
  • 11.28.3 Teijin Pharma Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.28.4 Teijin Pharma Ltd Products Offered
  • 11.28.5 Teijin Pharma Ltd Related Developments
• 11.29 WAVE Life Sciences Ltd
  • 11.29.1 WAVE Life Sciences Ltd Corporation Information
  • 11.29.2 WAVE Life Sciences Ltd Description and Business Overview
  • 11.29.3 WAVE Life Sciences Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.29.4 WAVE Life Sciences Ltd Products Offered
  • 11.29.5 WAVE Life Sciences Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Duchenne Muscular Dystrophy Drugs Market Estimates and Projections by Region
  • 12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2021-2026
• 12.2 North America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
  • 12.2.1 North America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
  • 12.2.2 North America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
  • 12.2.3 North America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
• 12.3 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
  • 12.3.2 Europe: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Duchenne Muscular Dystrophy Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Duchenne Muscular Dystrophy Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details